Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
NCT05728684 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2023-02-15
Summary
This study is a single-arm study initiated to evaluate the efficacy and safety of CM310 in subjects with recurrent IgG4-related disease.
Conditions
- IgG4 Related Disease
Interventions
- BIOLOGICAL
-
CM310
CM310 Injection
Sponsors & Collaborators
-
Beijing Friendship Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-02-28
- Primary Completion
- 2024-02-28
- Completion
- 2024-02-28
More Related Trials
-
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
NCT05662241 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
NCT04540497 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients
NCT05039190 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
NCT05332210 ·Status: COMPLETED ·Phase: PHASE3
-
Belimumab Treatment for IgG4-related Disease
NCT04660565 ·Status: UNKNOWN ·Phase: PHASE4
-
Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
NCT05716035 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
NCT06687174 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis
NCT07039578 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis
NCT00533091 ·Status: COMPLETED ·Phase: PHASE1
-
To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom
NCT03368274 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
NCT04561557 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Registered Cohort Study of Immune-Mediated Neuropathies
NCT04292834 ·Status: UNKNOWN
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
NCT05271409 ·Status: RECRUITING ·Phase: PHASE3
-
A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis
NCT02115997 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
NCT03772587 ·Status: COMPLETED ·Phase: PHASE2
-
GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases
NCT07021209 ·Status: RECRUITING ·Phase: PHASE1
-
JY231 Injection for the Treatment of Relapsed/Refractory Neurologic Immune Disorders
NCT06797024 ·Status: RECRUITING ·Phase: NA
-
CPI Combination Therapy for Autoimmune Encephalitis
NCT03542279 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients
NCT04346888 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
NCT05332587 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
NCT07265206 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
NCT07337785 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG
NCT06764160 ·Status: COMPLETED ·Phase: PHASE3
-
Seronegative Myasthenia Gravis - Efgartigimod IV
NCT06587867 ·Status: RECRUITING ·Phase: PHASE3
-
The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies
NCT03864185 ·Status: COMPLETED ·Phase: PHASE2